Association between platelet aggregation and diabetic complication in diabetes mellitus

1)血清肌酐（Cr）正常的糖尿病患者胞浆中PKC β的阳性率明显高于Cr异常（Cr ≤ 15 mg/dl）的糖尿病患者和健康人。磺脲类药物治疗的糖尿病患者血小板胞浆PKCβ免疫反应性明显高于健康对照组。此外，与磺脲类药物治疗的患者相比，胰岛素治疗的糖尿病患者的PKCβ免疫反应性明显受到抑制。提示慢性高血糖可激活血小板PKCβ亚型，胰岛素治疗可降低血小板PKCβ活性。2）糖尿病合并高血压可引起血小板内5-羟色胺含量降低。我们研究了17例糖尿病患者0.1U/ml凝血酶<14>刺激的血小板5-羟色胺释放。凝血酶诱导糖尿病患者血小板5-羟色胺释放的研究 ...更多信息 与对照组和无糖尿病的高血压患者相比，合并高血压的糖尿病患者凝血酶诱导的血小板5-羟色胺释放明显高于不合并高血压的糖尿病患者。17例糖尿病患者凝血酶诱导的5-羟色胺释放与糖尿病并发症的严重程度和糖尿病治疗无明显相关性。3）对13例未服用影响血小板功能药物的糖尿病亚组和9例正常对照组进行了血清瘦素浓度和激动剂诱导的血小板聚集的研究（6例男性，3例女性，平均年龄32.4 ±13.6岁，平均BMI 23.0±2.5 kg/m^2）。糖尿病组和对照组血清瘦素水平与BMI呈正相关。糖尿病合并症组与无合并症组血清瘦素水平无显著性差异。这些结果表明，ADP刺激的最大血小板聚集率可能与血清瘦素浓度在糖尿病患者。少

1)Plalelet PKC β immunoreacitivity in cytosol fraction was siguificantly higher in diabetic patients with normal serum creatinine(Cr)level than in diabetic patients with abnormal Cr level(Cr ≧ 15 mg/dl)or in healthy subjects. Platelet PKCβ immunoreactivity in cytosol from diabetic patients treated with sulphonylurea was significantly higher than that from healthy subujects. In addition, PKCβ immunoreactivity in diabetic patients with insulin treatment was significantly suppressed compared to that in patients treated by sulphonylurea treatment. These results suggest that chronic hyperglyecmia may activate platelet PKCβ isoform, and that insulin treatment may decrease platelet PKCβ activity.2)It has been reported that the presence of hypertension in diabetes causes a decrease in intraplatelet serotonin content. We investigated 0.1 U/ml thrombin-sutimulated[^<14>C]serotonin release from platelet in 17 diabetic subjects. Thrombin-induced serotonin release from platelet in diabetic subjects … More was significantly increased, compared with controls and hypertension without diabetes. Thrombin-induced platelet serotonin release in diabetic patients with hypertension was significantly higher than in diabetic patients without hypertension. There was no significant correlation among the severities of diabetic complication, and diabetic treatment in thrombin-induced serotonin release from 17 diabetic patients. Increased serotonin release from platelet in diabetes may contribute to the development of macroangiopathy in diabetes with hypertension.3)We studied serum leptin concentration ard agonist-induced platelet aggregation in platelets from 13 diabetic subujects who did not use the medicine which influenced the platelet function, and 9 contorol subjects(6 men, 3 woman, average age 32.4 ±13.6 years old, and average BMI 23.0±2.5 kg/m^2). It was observed positive correlation between the serum leptin concentration and BMI in both diabetic and control subjects. There was no significant difference of serum leptin concentration in diabetic subjects with and withouto diabetic complication. These results suggest that ADP-stimulated maximum platelet aggregation rate may be associated with serum leptin concentration in diabetic subjects. Less